{
    "nctId": "NCT06650423",
    "briefTitle": "Adherence to Aromatase Inhibitors \u00b1 Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer",
    "officialTitle": "ONCO-ADHER: Adherence to Treatment With a Aromatase Inhibitors With or Without Abemaciclib in Patients With Early-stage, Endocrine-dependent, HER-2-negative Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Early Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 319,
    "primaryOutcomeMeasure": "Medication adherence in proportion of days covered (PDC)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female,\n* Early HR+/HER-2- BC,\n* Patient is receiving adjuvant therapy with an aromatase inhibitor (letrozole, anastrozole or exemestane), with or without a CDK4/6 inhibitor abemaciclib, for no more than 18 months,\n* Treatment of BC is being conducted at OIL,\n* Patient has mandatory health insurance through Health Insurance Institute of Slovenia,\n* Patient understands Slovenian language, and\n* Patient agrees to participate in the study and provides written informed consent.\n\nExclusion Criteria:\n\n* Metastatic HR+/HER-2- BC\n* Previous treatment for BC with an aromatase inhibitor, with or without a CDK4/6 inhibitor, due to BC.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}